Johnson & Johnson SG&A Expenses 2010-2024 | JNJ

Johnson & Johnson annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
  • Johnson & Johnson sg&a expenses for the quarter ending September 30, 2024 were $5.478B, a 1.44% increase year-over-year.
  • Johnson & Johnson sg&a expenses for the twelve months ending September 30, 2024 were $22.226B, a 18.17% increase year-over-year.
  • Johnson & Johnson annual sg&a expenses for 2023 were $21.512B, a 6.25% increase from 2022.
  • Johnson & Johnson annual sg&a expenses for 2022 were $20.246B, a 0.64% increase from 2021.
  • Johnson & Johnson annual sg&a expenses for 2021 were $20.118B, a 8.9% decline from 2020.
Johnson & Johnson Annual SG&A Expenses
(Millions of US $)
2023 $21,512
2022 $20,246
2021 $20,118
2020 $22,084
2019 $22,178
2018 $22,540
2017 $21,520
2016 $20,067
2015 $21,203
2014 $21,954
2013 $21,830
2012 $20,869
2011 $20,969
2010 $19,424
2009 $19,801
Johnson & Johnson Quarterly SG&A Expenses
(Millions of US $)
2024-09-30 $5,478
2024-06-30 $5,681
2024-03-31 $5,257
2023-12-31 $5,810
2023-09-30 $5,400
2023-06-30 $5,396
2023-03-31 $4,906
2022-12-31 $3,107
2022-09-30 $4,975
2022-06-30 $6,226
2022-03-31 $5,938
2021-12-31 $2,613
2021-09-30 $6,000
2021-06-30 $6,073
2021-03-31 $5,432
2020-12-31 $6,457
2020-09-30 $5,431
2020-06-30 $4,993
2020-03-31 $5,203
2019-12-31 $6,039
2019-09-30 $5,374
2019-06-30 $5,546
2019-03-31 $5,219
2018-12-31 $5,991
2018-09-30 $5,543
2018-06-30 $5,743
2018-03-31 $5,263
2017-12-31 $6,045
2017-09-30 $5,423
2017-06-30 $5,289
2017-03-31 $4,763
2016-12-31 $5,431
2016-09-30 $4,772
2016-06-30 $5,176
2016-03-31 $4,688
2015-12-31 $5,891
2015-09-30 $5,081
2015-06-30 $5,384
2015-03-31 $4,847
2014-12-31 $5,822
2014-09-30 $5,468
2014-06-30 $5,481
2014-03-31 $5,183
2013-12-31 $5,917
2013-09-30 $5,314
2013-06-30 $5,376
2013-03-31 $5,223
2012-12-31 $5,661
2012-09-30 $5,228
2012-06-30 $4,965
2012-03-31 $5,015
2011-12-31 $5,458
2011-09-30 $5,240
2011-06-30 $5,215
2011-03-31 $5,056
2010-12-31 $5,180
2010-09-30 $4,709
2010-06-30 $4,756
2010-03-31 $4,779
2009-12-31 $5,629
2009-09-30 $4,767
2009-06-30 $4,797
2009-03-31 $4,608
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.366B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94